v3 Template
K

Kailera Therapeutics

Biopharmaceuticals Waltham, MA and San Diego, CA ~120 employees
Founded
--
Employees (Est.)
~120
8 leaders known
Total Funding
$2.3B
Funding Rounds
4
Last Funding
2026-04-20

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of next-generation therapies for obesity and related conditions. Their mission is to empower people to transform their lives through innovative treatments that enhance overall health, backed by a commitment to scientific and clinical excellence.

Products & Services

KAI-9531 Injectable:A GLP-1/GIP receptor dual agonist formulated as an injectable peptide in clinical development for the treatment of obesity and type 2 diabetes.
ribupatide
four clinical-stage GLP-1-based product candidates

Specialties

Obesity therapies GLP-1/GIP receptor agonists Oral and injectable peptide therapies Type 2 diabetes treatments Clinical-stage drug development obesity therapeutics GLP-1 mechanisms of action

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: IPO
T: -
FT: IPO
A: 718800000
MR: -
FA: $718.8 million
FAN: 718800000
D: 2026-04-20
FD: 2026-04-20
6 investors
2 RT: IPO
T: -
FT: IPO
A: 625000000
MR: -
FA: $625.0 million
FAN: 625000000
D: 2026-04-16
FD: 2026-04-16
6 investors
3 RT: Series B
T: -
FT: Series B
A: 600000000
MR: -
FA: $600 million
FAN: 600000000
D: 2025-10-14
FD: 2025-10-14
15 investors
4 RT: Series A
T: -
FT: Series A
A: 400000000
MR: -
FA: $400 million
FAN: 400000000
D: 2024-10-01
FD: 2024-10-01
4 investors
IPO Latest
2026-04-20
$718.8M
6 investors (Pro only)
IPO 2026-04-16
$625.0M
Series B 2025-10-14
$600.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

R

Ron Renaud

President & Chief Executive Officer

R

Ron Renaud

President & Chief Executive Officer

S

Scott Akamine

Chief Legal Officer

P

Paul Burgess

Chief Operating Officer & Chief Business Officer

P

Paula Cloghessy

Chief People Officer

J

Jamie Coleman

Chief Commercial Officer

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

Kailera Therapeutics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceuticals
Company Size
~120 employees (est.)
Locations
Waltham, MA and San Diego, CA

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro